New Mass Spectrometry Series Enhances Analytical Diagnostics

A leading mass spectrometry portfolio for analytic clinical testing has been expanded with a new series offering flexibility, exceptional sensitivity, and faster data acquisition.

SCIEX Diagnostics (Framingham, MA, USA), part of AB SCIEX, unveiled its latest products—theTriple Quad 4500MD and QTRAP 4500MD LC/MS/MS systems—at the American Association of Clinical Chemistry (AACC) Annual Meeting and Expo in Chicago, Illinois, July 29–31, 2014. Expected to be available in the US and select EU countries in September 2014, the 4500MD series joins the company's growing family of in vitro diagnostic devices, including the 3200MD and IVD-MS Analyzer systems launched in 2013, as well as a series of kits for vitamin D, immunosuppressants, and newborn screening testing to be available in August 2014 for use in certain European countries.

The new 4500MD series offers exceptional sensitivity and faster data acquisition over previous systems, providing reliable results so physicians and patients have accurate answers quickly. It is a flexible LC/MS/MS platform that offers enhanced performance to enable customers developing their own applications to validate methods that require lower detection limits or higher throughput, with the peace of mind afforded by a regulatory compliant solution.

"As scientific understanding progressively evolves into improved clinical diagnostic testing, diagnostic customers who develop their own assays are turning to fast, sensitive instruments to perform routine tests with high efficiency and cost savings," said Chris Radloff, vice president of Applied Markets and Clinical Research at AB SCIEX, "By bringing the power, flexibility, reliability, and accuracy of our mass spectrometry technology to clinical testing laboratories, AB SCIEX is enabling customers to deliver high quality diagnostic information to clinicians who make decisions affecting patient care."

Related Links:

SCIEX Diagnostics
AB SCIEX